Navigation Links
Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
Date:9/19/2007

Novel Antibiotic Candidate Rapidly Bactericidal Against Both Cultures and

Spores of the Anaerobic Bacterium Using Multiple in Vitro Methods

CHICAGO, Sept. 19 /PRNewswire/ -- Targanta Therapeutics Corporation today released data from two studies comparing the in vitro activity of its lead antibiotic drug candidate, oritavancin, to that of other antibiotics against Clostridium difficile bacteria. Results are being presented today at the 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) taking place in Chicago, IL.

C. difficile are anaerobic, gram-positive, spore-forming bacteria that are a major cause of morbidity in the hospitalized elderly. C. difficile infection is associated with many diseases, the most significant of which are uncomplicated diarrhea and pseudomembranous colitis, or severe infection of the colon. Often, after normal gut flora are eradicated by the use of antibiotics, it is postulated that C. difficile spores refractory to current antimicrobial therapies persist, causing recurrent infections. The U.S. Centers for Disease Control and Prevention (CDC) reports that each year nearly 10 percent of all hospitalized patients, or two million patients, contract C. difficile infections during their stay.

In the first study, presented as a poster entitled "In Vitro Susceptibility of Genotypically Distinct Clostridium difficile Strains to Oritavancin," researchers tested the activity of oritavancin versus the standards of care, metronidazole and vancomycin, against 33 genotypically distinct strains of C. difficile bacteria. Overall, in this study, oritavancin was more active than either metronidazole or vancomycin, and oritavancin was more active than vancomycin against 94% of the C. difficile strains tested by the broth macrodilution method.

In the second study, accepted as a late-breaker poster presentation entitled "Activity of Metronidazole, Vancomycin and Oritavancin Against Epidemic C
'/>"/>

SOURCE Targanta Therapeutics Corporation
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Targanta Study Shows Oritavancin Treatment Effective in a Mouse Model of Anthrax
2. Targanta Reports Improved Ability of Oritavancin to Stop Bacteria Growth In Vitro Compared With Other Glycopeptide Antibiotics
3. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
4. Publication on Pixantrone Preclinical Studies Demonstrates Reduced Cardiotoxicity Compared to Equiactive Doses of Doxorubicin and Mitoxantrone
5. New Research Demonstrates Broad Efficacy of Azixa (MPC-6827) Against Multiple Tumor Types and in Drug Resistant Cell Lines
6. Algeta Demonstrates Targeted Cancer-killing Potential of Novel Alpha Particle Linked Antibodies in Leading Medical Journal Blood
7. Gerons Telomerase Inhibitor Cancer Drug Demonstrates Good Pharmacokinetics and Tolerability in Phase I/II Trial
8. Frova Phase III Study Data Demonstrates That Short-Term Prevention Treatment Reduces Frequency and Severity of Menstrual Migraine
9. Mymetics HIV Vaccine Demonstrates First-Ever Production of Neutralizing IgA Antibodies in Non-Human Primate Model
10. Cipralex demonstrates superiority to duloxetine for acute treatment of depression in new study
11. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Feb. 27, 2015  Pomerantz LLP is ... Inc. ("Vitae" or the "Company") (NASDAQ: VTAE ... S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ... and certain of its officers and/or directors have violated ... of 1934.  On February 27, 2015, ...
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... in the Proceedings of the National Academy ... when ibrutinib (IMBRUVICA ® ) was combined with ... tumor growth was enhanced suggesting a greater response ... and solid tumors with the combination. IMBRUVICA is ...
(Date:2/27/2015)...  Acsis Inc., the market leader for supply chain ... John DiPalo , Acsis, Chief Strategy Officer, has ... Executive 2015 Provider Pro to Know. The award ... help prepare their companies, and customers, supply chains for ... list of Provider Pros to Know is featured in ...
Breaking Medicine Technology:SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Vitae Pharmaceuticals, Inc. - VTAE 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 2In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 3In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 4In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 5In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 6In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 7In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 8In Pre-Clinical Studies Ibrutinib Enhances Anti-tumor Activity When Combined With An Anti-PD-L1 Antibody 9Acsis CSO John DiPalo Named Supply & Demand Chain Executive 2015 Pro to Know 2
... AcelRx Pharmaceuticals, Inc. announced today that results ... of its oral transmucosal NanoTab(TM) formulation of sufentanil ... the upcoming American Society of Anesthesiologists Annual Meeting ... Officer of AcelRx, will present in the following ...
... Oct. 15 Azopharma Product Development Group, LLC, ... services and PharmaNet Development Group, Inc., a leading ... biotechnology, generic drug and medical device companies, are ... development and co-promotion alliance to leverage complementary services, ...
Cached Medicine Technology:Azopharma and PharmaNet Development Group Enter Preclinical Strategic Alliance 2
(Date:2/27/2015)... Cary, NC (PRWEB) February 27, 2015 ... nation’s leading cancer research funding organizations, is excited to ... varied ways to participate and many long-standing partnerships highlight ... cancer and focus on expanding ways for all to ... cash donations to cutting-edge cancer research, The V Foundation ...
(Date:2/27/2015)... The federal court overseeing more than ... of the statin medication can increase a person’s risk ... order pertaining discovery in the cases selected for the ... The Order, which was issued in the U.S. District ... the parties to schedule certain witness depositions before May ...
(Date:2/27/2015)... Royal River Natural Foods, a locally-owned independent natural ... found adults who got the most magnesium were less than ... those who got the least magnesium, with the largest benefit ... is part of the March 2015 issue of “ Natural ... publishes free each month for the Freeport community to learn ...
(Date:2/27/2015)... Wisconsin (PRWEB) February 27, 2015 Dr. ... plastic surgeons , is pleased to announce the expansion ... now open in Delafield. Quintessa has begun seeing patients ... the new Delafield location will offer a variety of ... including: Botox, filler injectables, micro laser peels, chemical peels, ...
(Date:2/27/2015)... Chicago, IL (PRWEB) February 27, 2015 ... at Lutheran General Hospital on June 25, 2013 and ... into her stomach through her mouth. Because the ... became infected with the antibiotic-resistant “superbug” carbapenem-resistant Enterobacteriaceae (CRE). ... the Circuit Court of Cook County on behalf of ...
Breaking Medicine News(10 mins):Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 2Health News:The V Foundation Reinforces its Fight Against Cancer with New and Extended Partnerships 3Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 2Health News:Federal Lipitor Litigation Issues New Order Pertaining to Discovery in Bellwether Cases, Bernstein Liebhard LLP Comments 3Health News:New Study Finds Magnesium May Slow Progress of Diabetes, Retailer Reports 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 2Health News:Dr. Andrew Campbell Expands Quintessa Aesthetic Center into Delafield 3Health News:Lawsuit Alleges Blame on Scope Manufacturer for "Superbug" Outbreak 2
... Cards Celebrates its 50th anniversary this holiday season, ... of nonprofit,Minneapolis-based Courage Center, announces its new 2008 ... season, Courage Cards is,celebrating its 50th anniversary as ... to announce our 2008 Courage Cards artists:, ...
... (NYSE:,CNO) will host a conference call to discuss ... at 10:00 a.m. Eastern Daylight,Time., On August ... a more,detailed description of the company,s investment portfolio ... this supplement can be accessed through the Investors ...
... 8 The U.S. Department of,Veterans Affairs (VA) ... veterans, voter registration activities, with particular focus on,inpatients ... and,patients with limited access to community voter registration ... local election officials and,non-partisan groups to its hospitals ...
... gene therapy at the University of Florida to treat a ... vision, according to a paper published online today in ... and two men ranging from 21 to 24 years old ... type 2 volunteered to test the safety of an ...
... Collaborative of major health plans launches online toolkit ... in health care, WASHINGTON, Sept. 8 ... toolkit of resources, lessons, case,studies and videos to ... memberships., The Collaborative brings together 11 major ...
... Parents probably,wouldn,t have guessed, but kids like soyfoods. ... soyfoods as much as meat,counterparts. The trick -- ... soyfoods., A plate waste study, funded by ... macaroni & cheese, burgers, chicken nuggets, and,chicken Caesar ...
Cached Medicine News:Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 2Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 3Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 4Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 5Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 6Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 7Health News:Courage Cards Announces 2008 Fine Art Holiday Greeting Card Collection 8Health News:Conseco Announces Call on Investment Portfolio Supplement 2Health News:VA Clarifies Voter Registration Regulations 2Health News:Safety study indicates gene therapy for blindness improves vision 2Health News:Safety study indicates gene therapy for blindness improves vision 3Health News:National Health Plan Collaborative Launches Online Toolkit to Assist Health Plans in Reducing Disparities 2Health News:Back to School With Soy 2
... Hip Stabilizer Abduction and ... replacements, revisions and fractures. ... abduction with adjustable flexion ... settings. Adjustabelt back panel. ...
... low cost walker features a non-skid rocker ... low profile design minimizes leg length discrepancies. ... makes strapping quick and easy. Steel uprights ... swollen ankles and extra bandaging. This extra ...
... and Cronin, Inc. is ... Patient Footwear, Orthopedic Softgoods, ... Products. Our products are ... and available in the ...
... Walker is a short pneumatic walking brace ... Because of its shorter height it is ... calf circumference prohibits them from using a ... for patient comfort while providing superior injury ...
Medicine Products: